Compass Therapeutics, Inc.(CMPX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CMPX Compass Therapeutics, Inc.

盘后交易 06-04 19:23:06 EDT

2.13

+0.03

+1.43%

盘后2.11

-0.02-0.94%

18:26 EDT

最高2.18	最低2.07	成交量447.77万
今开2.07	昨收2.10	日振幅5.00%
总市值3.84亿	流通市值2.53亿	总股本1.80亿
成交额950.33万	换手率3.76%	流通股本1.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CMPX","market":"US","secType":"STK","nameCN":"Compass Therapeutics, Inc.","latestPrice":2.13,"timestamp":1780603200000,"preClose":2.1,"halted":0,"volume":4477692,"hourTrading":{"tag":"盘后","latestPrice":2.11,"preClose":2.13,"latestTime":"18:26 EDT","volume":18965,"amount":40364.108441,"timestamp":1780611994496,"change":-0.02,"changeRate":-0.00939,"amplitude":0.00939},"delay":0,"changeRate":0.014285714285714192,"floatShares":119000000,"shares":180087915,"eps":-0.4,"marketStatus":"盘后交易","change":0.03,"latestTime":"06-04 19:23:06 EDT","open":2.07,"high":2.175,"low":2.07,"amount":9503255.1390444,"amplitude":0.05,"askPrice":2.12,"askSize":111,"bidPrice":2.06,"bidSize":99,"shortable":3,"etf":0,"ttmEps":-0.4,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1780617600000},"marketStatusCode":4,"adr":0,"listingDate":1605243600000,"exchange":"NASDAQ","adjPreClose":2.1,"preHourTrading":{"tag":"盘前","latestPrice":2.07,"preClose":2.1,"latestTime":"09:29 EDT","volume":53202,"amount":108655.827852,"timestamp":1780579799999,"change":-0.03,"changeRate":-0.014286,"amplitude":0.033333},"postHourTrading":{"tag":"盘后","latestPrice":2.11,"preClose":2.13,"latestTime":"18:26 EDT","volume":18965,"amount":40364.108441,"timestamp":1780611994496,"change":-0.02,"changeRate":-0.00939,"amplitude":0.00939},"volumeRatio":0.88522,"impliedVol":1.1074,"impliedVolPercentile":0.506},"requestUrl":"/m/hq/s/CMPX","defaultTab":"news","newsList":[{"id":"1115226740","title":"Compass Therapeutics股价暴跌72.2% 盘前交易报1.40美元 Tovecimig试验结果引发震荡","url":"https://stock-news.laohu8.com/highlight/detail?id=1115226740","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115226740?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:52","pubTimestamp":1777294329,"startTime":"0","endTime":"0","summary":"生物制药公司Compass Therapeutics, Inc.股价遭遇断崖式下跌，在盘前交易中重挫72.2%，报收于1.40美元。此次股价异动源于其核心药物Tovecimig的临床试验结果公布，市场反应剧烈。\n该治疗药物的试验数据未能达到投资者预期，导致资本纷纷撤离。股价的急剧下滑反映出市场对该公司研发前景的重新评估，也凸显了生物科技领域投资的高风险特性。\n业内人士指出，此次股价波动将对公司融资能力和后续研发计划产生深远影响。投资者正密切关注公司管理层后续应对措施及药物研发路径的调整方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132083489","title":"Compass Therapeutics公司达成PFS关键次要终点 随机COMPANION-002研究展现更多积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1132083489","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132083489?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:48","pubTimestamp":1777290508,"startTime":"0","endTime":"0","summary":"Compass Therapeutics公司宣布，其随机COMPANION-002研究不仅达到了无进展生存期（PFS）的关键次要终点，更呈现出多项令人鼓舞的额外研究成果。该临床试验结果的突破性进展，为公司在肿瘤免疫治疗领域的创新药物研发注入了强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149046102","title":"Tovecimig在胆道癌患者随机II/III期Companion-002研究中展现统计学显著获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1149046102","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149046102?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:41","pubTimestamp":1777290065,"startTime":"0","endTime":"0","summary":"Tovecimig在针对胆道癌患者的随机II/III期Companion-002临床研究中，成功证明了其具有统计学意义的显著临床获益。该研究结果标志着这一疗法在胆道癌治疗领域取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167042333","title":"Compass Therapeutics公司：Tovecimig联合紫杉醇将中位无进展生存期提升至4.7个月，显著优于对照组的2.6个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1167042333","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167042333?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:36","pubTimestamp":1777289797,"startTime":"0","endTime":"0","summary":"Compass Therapeutics公司最新临床研究数据显示，其研发的Tovecimig与紫杉醇联合用药方案取得突破性进展——治疗组中位无进展生存期达到4.7个月，较对照组单用紫杉醇的2.6个月实现显著提升。该数据表明双药联合疗法可使患者疾病进展风险降低约44%，为晚期癌症治疗提供新的有效方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191452051","title":"Compass Therapeutics公司：CTX-471针对表达NCAM（CD56）肿瘤患者的二期临床试验预计2026年上半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1191452051","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191452051?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:09","pubTimestamp":1767704958,"startTime":"0","endTime":"0","summary":"生物技术公司Compass Therapeutics近日宣布，其核心候选药物CTX-471针对表达神经细胞黏附分子（NCAM，亦称CD56）的实体瘤患者的二期临床试验，预计将于2026年上半年正式启动。这一进展标志着该创新疗法在肿瘤免疫治疗领域迈出了关键一步。\nCTX-471作为一种靶向CD112R和TIGIT的双特异性抗体，旨在激活T细胞和自然杀伤（NK）细胞，增强机体对肿瘤的免疫应答能力。二期试验将重点评估该药物在特定患者群体中的安全性与有效性，为后续临床开发提供重要数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131557936","title":"Compass Therapeutics公司Ctx-10726一期临床试验预计2026年一季度启动，初步数据将于下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1131557936","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131557936?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:04","pubTimestamp":1767704655,"startTime":"0","endTime":"0","summary":"生物技术公司Compass Therapeutics宣布，其创新药物Ctx-10726的一期临床研究计划于2026年第一季度正式启动。该项目旨在评估该候选药物的安全性与耐受性，初步临床数据预计在2026年下半年揭晓。此次试验进展标志着公司在肿瘤治疗领域研发管线的重要推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518227999","title":"Compass Therapeutics, Inc.盘中异动 股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518227999","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518227999?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:00","pubTimestamp":1741615207,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时00分，Compass Therapeutics, Inc.股票出现波动，股价急速下跌5.02%。Compass Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3054.58%、660.55%、279.68%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Impact Biomedical, Inc.，振幅分别为41.36%、40.24%、28.59%。Compass Therapeutics, Inc.公司简介：Compass Therapeutics Inc 是一家临床阶段生物制药公司，致力于开发专有抗体疗法，旨在参与免疫系统治疗实体瘤和血液恶性肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022000798a2a46d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022000798a2a46d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CMPX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517430106","title":"Compass Therapeutics, Inc.2024财年实现净利润-49.38百万美元，同比减少16.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517430106","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517430106?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363244,"startTime":"0","endTime":"0","summary":"3月8日，Compass Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-49.38百万美元，同比减少16.22%；其中营业收入为850000.00美元，每股基本收益为-0.36美元。从资产负债表来看，Compass Therapeutics, Inc.总负债15.17百万美元，其中短期债务338000.00美元，资产负债比为0.10，流动比率为0.15。机构评级：截至2025年3月8日，当前有10家机构对Compass Therapeutics, Inc.目标价做出预测，其中目标均价为11.40美元，其中最低目标价为4.00美元，最高目标价为32.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000139abed6624&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000139abed6624&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517100239","title":"Compass Therapeutics, Inc.盘中异动 早盘快速拉升5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517100239","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517100239?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:34","pubTimestamp":1741185265,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时34分，Compass Therapeutics, Inc.股票出现波动，股价快速上涨5.04%。Compass Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Zyversa Therapeutics, Inc.较为活跃，换手率分别为376.37%、260.67%、187.87%，振幅较大的相关个股有Aditxt, Inc.、Silexion Therapeutics Corp、Invivyd, Inc.，振幅分别为23.90%、19.80%、13.32%。Compass Therapeutics, Inc.公司简介：Compass Therapeutics Inc 是一家临床阶段生物制药公司，致力于开发专有抗体疗法，旨在参与免疫系统治疗实体瘤和血液恶性肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223425abe9b1b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223425abe9b1b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CMPX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516630029","title":"Compass Therapeutics, Inc.盘中异动 股价大跌5.00%报2.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516630029","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516630029?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:32","pubTimestamp":1741015956,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时32分，Compass Therapeutics, Inc.股票出现波动，股价急速跳水5.00%。Compass Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.25%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Aldeyra Therapeutics, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为2104.08%、136.31%、127.51%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为177.97%、70.53%、48.34%。Compass Therapeutics, Inc.公司简介：Compass Therapeutics Inc 是一家临床阶段生物制药公司，致力于开发专有抗体疗法，旨在参与免疫系统治疗实体瘤和血液恶性肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303233236989a1fd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303233236989a1fd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CMPX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514832040","title":"Compass Therapeutics, Inc.盘中异动 早盘股价大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514832040","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514832040?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753084,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Compass Therapeutics, Inc.股票出现波动，股价快速上涨5.17%。Compass Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Tc Biopharm  Plc C/Wts 10/02/2028 、Anaptysbio, Inc.、Enveric Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Virpax Pharmaceuticals, Inc.、Enveric Biosciences, Inc.较为活跃，换手率分别为480.35%、239.11%、55.70%，振幅较大的相关个股有Trevi Therapeutics, Inc.、Enanta Pharmaceuticals, Inc.、Aardvark Therapeutics, Inc.，振幅分别为7.11%、6.58%、6.22%。Compass Therapeutics, Inc.公司简介：Compass Therapeutics Inc 是一家临床阶段生物制药公司，致力于开发专有抗体疗法，旨在参与免疫系统治疗实体瘤和血液恶性肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223124abe0ea1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223124abe0ea1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183125006","title":"Compass Therapeutics 第四季度每股亏损$(0.11) 不及预期$(0.10)","url":"https://stock-news.laohu8.com/highlight/detail?id=1183125006","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183125006?lang=zh_cn&edition=full","pubTime":"2025-02-27 21:22","pubTimestamp":1740662579,"startTime":"0","endTime":"0","summary":"Compass Therapeutics报告称，季度每股亏损$，较分析师普遍预计的每股亏损$低10%。这与去年同期持平。以上内容来自Benzinga Earnings专栏，原文如下：Compass $Therapeutics$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 10 percent. This is unchanged from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514013098","title":"Compass Therapeutics, Inc.盘中异动 早盘股价大跌5.02%报2.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514013098","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514013098?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:03","pubTimestamp":1740495829,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时03分，Compass Therapeutics, Inc.股票出现波动，股价大幅跳水5.02%。Compass Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.05%。Compass Therapeutics, Inc.公司简介：Compass Therapeutics Inc 是一家临床阶段生物制药公司，致力于开发专有抗体疗法，旨在参与免疫系统治疗实体瘤和血液恶性肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225230350962ffa30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225230350962ffa30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513277637","title":"Compass Therapeutics(CMPX.US)获Guggenheim首次覆盖，给予买入评级, 目标价12.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513277637","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513277637?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:51","pubTimestamp":1740408709,"startTime":"0","endTime":"0","summary":"Compass Therapeutics(CMPX.US)获Guggenheim首次覆盖，给予买入评级, 目标价12.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24225148353022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513843720","title":"Compass Therapeutics, Inc.盘中异动 股价大涨5.82%报3.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513843720","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513843720?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:31","pubTimestamp":1740407465,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时31分，Compass Therapeutics, Inc.股票出现异动，股价大幅拉升5.82%。Compass Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Aditxt, Inc.、Pepgen Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为39.11%、24.28%、23.21%，振幅较大的相关个股有Pepgen Inc.、Estrella Immunopharma, Inc.、Invivyd, Inc.，振幅分别为11.68%、11.49%、9.04%。Compass Therapeutics, Inc.公司简介：Compass Therapeutics Inc 是一家临床阶段生物制药公司，致力于开发专有抗体疗法，旨在参与免疫系统治疗实体瘤和血液恶性肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223105abdb0d8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223105abdb0d8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513158642","title":"Compass Therapeutics, Inc.盘中异动 快速跳水5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513158642","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513158642?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:31","pubTimestamp":1740159102,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日01时31分，Compass Therapeutics, Inc.股票出现异动，股价大幅下挫5.03%。Compass Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.35%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Osr Holdings, Inc.、Invivyd, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为240.46%、228.02%、129.58%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为72.46%、57.50%、48.35%。Compass Therapeutics, Inc.公司简介：Compass Therapeutics Inc 是一家临床阶段生物制药公司，致力于开发专有抗体疗法，旨在参与免疫系统治疗实体瘤和血液恶性肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222013142a24ed778&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222013142a24ed778&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512416166","title":"Compass Therapeutics, Inc.盘中异动 股价大涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512416166","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512416166?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:34","pubTimestamp":1739889286,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时34分，Compass Therapeutics, Inc.股票出现异动，股价大幅拉升5.18%。Compass Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.04%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Aditxt, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为283.70%、99.59%、74.80%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Allogene Therapeutics, Inc.、Glycomimetics, Inc.，振幅分别为34.04%、22.30%、18.69%。Compass Therapeutics, Inc.公司简介：Compass Therapeutics Inc 是一家临床阶段生物制药公司，致力于开发专有抗体疗法，旨在参与免疫系统治疗实体瘤和血液恶性肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223446a24aad82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223446a24aad82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511524021","title":"Compass Therapeutics, Inc.盘中异动 早盘大幅下挫5.07%报3.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511524021","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511524021?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:51","pubTimestamp":1739461919,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时51分，Compass Therapeutics, Inc.股票出现波动，股价急速下跌5.07%。Compass Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.53%。Compass Therapeutics, Inc.公司简介：Compass Therapeutics Inc 是一家临床阶段生物制药公司，致力于开发专有抗体疗法，旨在参与免疫系统治疗实体瘤和血液恶性肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213235159abcdc221&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213235159abcdc221&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510633600","title":"Compass Therapeutics, Inc.盘中异动 早盘股价大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510633600","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510633600?lang=zh_cn&edition=full","pubTime":"2025-02-12 00:02","pubTimestamp":1739289722,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日00时02分，Compass Therapeutics, Inc.股票出现波动，股价大幅下跌5.13%。Compass Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.72%。其相关个股中，Ocean Biomedical, Inc.、Dominari Holdings Inc.、Lipella Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2761.03%、1204.40%、395.51%，振幅较大的相关个股有Dominari Holdings Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.，振幅分别为58.60%、57.43%、40.87%。Compass Therapeutics, Inc.公司简介：Compass Therapeutics Inc 是一家临床阶段生物制药公司，致力于开发专有抗体疗法，旨在参与免疫系统治疗实体瘤和血液恶性肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212000202961f58a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212000202961f58a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CMPX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510888815","title":"杰富瑞投资银行：维持Compass Therapeutics(CMPX.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至8.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510888815","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510888815?lang=zh_cn&edition=full","pubTime":"2025-02-11 05:32","pubTimestamp":1739223143,"startTime":"0","endTime":"0","summary":"杰富瑞投资银行：维持Compass Therapeutics(CMPX.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至8.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/11053248064826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CMPX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.compasstherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0749},{"period":"1month","weight":0.0825},{"period":"3month","weight":-0.6203},{"period":"6month","weight":-0.6203},{"period":"1year","weight":-0.0187},{"period":"ytd","weight":-0.6089}],"compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":0.0505},{"period":"3month","weight":0.107},{"period":"6month","weight":0.1},{"period":"1year","weight":0.2653},{"period":"ytd","weight":0.1061}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Compass Therapeutics, Inc.最初于2018年3月20日在特拉华州注册成立，名称为Olivia Ventures, Inc.。2020年6月17日，该公司更名为Compass Therapeutics, Inc.。该公司是一家临床阶段的生物制药公司，开发专有抗体疗法，旨在利用免疫系统治疗实体瘤和血液系统恶性肿瘤。该公司的免疫肿瘤学候选产品包括临床阶段的单克隆抗体和双特异性抗体组合。这些候选产品旨在解决对癌症有效免疫反应所需的三个关键成分：诱导强大的先天免疫反应；激活适应性免疫系统；以及减轻肿瘤逃避免疫监视和激活的免疫抑制机制。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.118622},{"month":2,"riseRate":0.4,"avgChangeRate":0.052033},{"month":3,"riseRate":0.2,"avgChangeRate":-0.151702},{"month":4,"riseRate":0.2,"avgChangeRate":-0.191681},{"month":5,"riseRate":0.5,"avgChangeRate":0.179516},{"month":6,"riseRate":0.5,"avgChangeRate":-0.012329},{"month":7,"riseRate":0.6,"avgChangeRate":0.017507},{"month":8,"riseRate":0.6,"avgChangeRate":0.058578},{"month":9,"riseRate":0.4,"avgChangeRate":-0.036741},{"month":10,"riseRate":0.4,"avgChangeRate":0.029035},{"month":11,"riseRate":0.6,"avgChangeRate":0.162335},{"month":12,"riseRate":0.2,"avgChangeRate":-0.003054}],"exchange":"NASDAQ","name":"Compass Therapeutics, Inc.","nameEN":"Compass Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Compass Therapeutics, Inc.(CMPX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Compass Therapeutics, Inc.(CMPX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Compass Therapeutics, Inc.,CMPX,Compass Therapeutics, Inc.股票,Compass Therapeutics, Inc.股票老虎,Compass Therapeutics, Inc.股票老虎国际,Compass Therapeutics, Inc.行情,Compass Therapeutics, Inc.股票行情,Compass Therapeutics, Inc.股价,Compass Therapeutics, Inc.股市,Compass Therapeutics, Inc.股票价格,Compass Therapeutics, Inc.股票交易,Compass Therapeutics, Inc.股票购买,Compass Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Compass Therapeutics, Inc.(CMPX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Compass Therapeutics, Inc.(CMPX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}